Pfizer Inc (PFE)

PFE on New York Consolidated

34.96USD
31 Mar 2015
Change (% chg)

$-0.04 (-0.11%)
Prev Close
$35.00
Open
$34.89
Day's High
$35.00
Day's Low
$34.76
Volume
4,301,959
Avg. Vol
30,276,004
52-wk High
$35.45
52-wk Low
$27.51

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $214,911.70
Shares Outstanding(Mil.): 6,140.33
Dividend: 0.28
Yield (%): 3.20

Financials

  PFE Industry Sector
P/E (TTM): 24.69 40.53 41.01
EPS (TTM): 1.42 -- --
ROI: 6.17 16.83 16.17
ROE: 12.32 17.37 17.02
Search Stocks

Pfizer, Lilly to resume study testing pain drug

- Pfizer Inc and Eli Lilly and Co will resume late-stage studies of their drug tanezumab for chronic pain after the U.S. Food and Drug Administration lifted a partial hold on trials of it and similar medicines.

23 Mar 2015

UPDATE 2-Pfizer, Lilly to resume study testing pain drug

March 23 - Pfizer Inc and Eli Lilly and Co will resume late-stage studies of their drug tanezumab for chronic pain after the U.S. Food and Drug Administration lifted a partial hold on trials of it and similar medicines.

23 Mar 2015

UPDATE 1-Dementia drug research aided by $100 mln venture capital fund

* Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen

17 Mar 2015

UPDATE 1-Experimental cholesterol drugs cut heart risk, but questions remain

San Diego, March 15 - Studies of a new class of experimental cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack and other major cardiovascular problems compared to standard treatment alone.

15 Mar 2015

Endo's bid for Salix shows its strategy as Valeant challenger

- Endo International Plc's $11 billion offer this week for Salix Pharmaceuticals Ltd , an effort to trump an agreed $10 billion bid from Valeant Pharmaceutical Inc , illustrates CEO Rajiv De Silva's plan to be seen as not just a protege of Valeant chief Mike Pearson, but as a challenger.

12 Mar 2015

Pfizer hunts for new vaccines to protect young and old

LONDON - Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants.

12 Mar 2015

FDA warns of seizure, alcohol risk with Pfizer's Chantix

- The U.S. Food and Drug Administration warned on Monday that Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out.

09 Mar 2015

U.S. FDA warns of seizure, alcohol risk with Pfizer's Chantix

- The U.S. Food and Drug Administration warned on Monday that Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out.

09 Mar 2015

UPDATE 1-U.S. FDA warns of seizure, alcohol risk with Pfizer's Chantix

March 9 - The U.S. Food and Drug Administration warned on Monday that Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out.

09 Mar 2015

FDA declines to remove serious warning on Pfizer's Chantix

- The U.S. Food and Drug Administration has declined to reduce the severity of its warning about neuropsychiatric side effects associated with Pfizer Inc's quit-smoking drug Chantix, the agency said on Monday.

09 Mar 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.06 -0.49
Novartis AG (NOVN.VX) CHF96.45 -1.40
Merck & Co., Inc. (MRK.N) $58.04 -0.30
Roche Holding Ltd. (ROG.VX) CHF269.50 +4.50
Abbott Laboratories (ABT.N) $46.85 -0.23
Bayer AG (BAYGn.DE) €140.40 -1.95
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €92.05 -0.65
AstraZeneca plc (AZN.L) 4,639.50p -87.00
GlaxoSmithKline plc (GSK.L) 1,552.00p -32.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks